• Users Online: 98
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
RESEARCH ARTICLE
Year : 2019  |  Volume : 4  |  Issue : 1  |  Page : 7-13

Efficacy and safety of Mamajjaka Ghanavati in the treatment of type 2 diabetes mellitus: A prospective open label multi-center clinical study


1 Technical Department, Regional Ayurveda Research Institute for Metabolic Disorders (RARIMD), Bengaluru, Karnataka, India
2 Technical Department, Central Ayurveda Research Institute for Hepatobiliary Disorders (CARIHD), Bhubneshwar, India
3 Technical Department, Dr. AchantaLakshmipati Research Centre for Ayurveda (DALRCA), Chennai, India
4 Technical Department, Central Ayurveda Research Institute for Neuromuscular & Muscular-Skeletal Disorders (CARINMSD), Cheruthuruthy, Kerala, India
5 Technical Department, Central Council for Research in Ayurvedic Sciences, New Delhi, India
6 Technical Department, Central Ayurveda Research Institute for Drug Development (CARIDD), Kolkata, West Bengal, India
7 Technical Department, Regional Ayurveda Research Institute for Infectious Diseases(RARIID), Patna, Bihar, India

Correspondence Address:
Sarada Ota
Technical Department, Central Council for Research in Ayurvedic Sciences, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2542-3975.254106

Clinical trial registration CTRI/2017/09/009887

Rights and Permissions

Background and objectives: The purpose of this study is to investigate the efficacy and safety of Mamajjaka Ghanavati on blood glucose level, symptoms, and quality of life in patients with type 2 diabetes mellitus. Subjects and methods: This prospective, multi-center, open-label, single-arm clinical study was performed at three peripheral institutes of the Central Council for Research in Ayurvedic Sciences, New Delhi during April 2016 to May 2017. A total of 177 eligible patients with type 2 diabetes mellitus were included and administered Mamajjaka Ghanavati two tablets (500 mg each) twice daily after food for 84 days. At the end of the treatment period (84th day), the changes in Diabetes Symptom Questionnaire (i.e., glycosylated hemoglobin and fasting and postprandial blood sugar levels) were analyzed. Quality of life was evaluated using 36-Item Short Form Health Survey (SF-36). Clinical safety of Mamajjaka Ghanavati was assessed by liver and renal function tests. This study was approved by the Medical Ethics Committee of Central Council for Research in Ayurvedic Sciences, New Delhi (approval number: CTRI Reg No Ref/2016/06/011468) on March 14, 2016. Results: Compared to baseline data, after 84 days of treatment with Mamajjaka Ghanavati, Diabetes Symptom Questionnaire score was significantly decreased, and SF-36 score was significantly increased (both P < 0.01). However, compared to baseline data, no significant differences in glycated hemoglobin, fasting and postprandial blood sugar levels as well as hepatic and renal parameters were observed after 84 days of treatment with Mamajjaka Ghanavati. Conclusion: Mamajjaka Ghanavati can greatly improve the quality of life and is safe in the treatment of type 2 diabetes mellitus. Actually, Mamajjaka Ghanavati does not change blood sugar level greatly. Trial registration: This study was registered in the Clinical Trial Registry of India (CTRI/2017/09/009887) on September 22, 2017.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed157    
    Printed16    
    Emailed0    
    PDF Downloaded43    
    Comments [Add]    

Recommend this journal